Selling, General, and Administrative Costs: Perrigo Company plc vs Geron Corporation

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, managing costs is as crucial as innovation. From 2014 to 2023, Perrigo Company plc and Geron Corporation have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. Perrigo, a global leader in over-the-counter health products, consistently reported higher SG&A costs, peaking at approximately $1.27 billion in 2023. This represents a steady increase of about 89% from 2014. In contrast, Geron Corporation, a biopharmaceutical company focused on cancer treatments, saw its SG&A expenses rise by over 300% during the same period, reaching nearly $69 million in 2023. This stark difference highlights Perrigo's expansive operations compared to Geron's focused research-driven approach. As the industry evolves, these financial strategies will play a pivotal role in shaping their future trajectories.